Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Jean-Marc Ferran in
Google Scholar
PubMed
Search for other papers by Murray B Gordon in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Navid Nedjatian in
Google Scholar
PubMed
Search for other papers by Anne H Olsen in
Google Scholar
PubMed
Search for other papers by Matthias M Weber in
Google Scholar
PubMed
for AGHD (GH treated) who were enrolled in two non-interventional, multicentre studies: the NordiNet ® International Outcome Study (IOS) and the American Norditropin ® Studies: Web-Enabled Research (ANSWER) Program ( 16 , 17 ). The CV risks of
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Search for other papers by Thomas Edouard in
Google Scholar
PubMed
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy
Search for other papers by Mohamad Maghnie in
Google Scholar
PubMed
Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Alicia Romano in
Google Scholar
PubMed
Search for other papers by Martin Zenker in
Google Scholar
PubMed
Search for other papers by Reiko Horikawa in
Google Scholar
PubMed
mutation ( 9 , 18 ). Norditropin® (somatropin; Novo Nordisk A/S) is a recombinant human GH (rhGH) that is used as replacement therapy in patients with GHD or to treat a number of other conditions characterized by insufficient growth (US Food and Drug
Search for other papers by Robert Rapaport in
Google Scholar
PubMed
Search for other papers by Peter A Lee in
Google Scholar
PubMed
Nemours/DuPont Hospital for Children, Wilmington, Delaware, USA
Search for other papers by Judith L Ross in
Google Scholar
PubMed
Search for other papers by Paul Saenger in
Google Scholar
PubMed
Search for other papers by Vlady Ostrow in
Google Scholar
PubMed
Search for other papers by Giuseppe Piccoli in
Google Scholar
PubMed
developed as practical tools to estimate the response to GH therapy for the diagnosis of growth hormone deficiency (GHD) ( 19 ), SGA ( 20 ) and ISS ( 21 ). The non-interventional American Norditropin Studies: Web-Enabled Research (ANSWER) Program was
Search for other papers by Alicia Romano in
Google Scholar
PubMed
Search for other papers by Juan Pablo Kaski in
Google Scholar
PubMed
Search for other papers by Jovanna Dahlgren in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed
Search for other papers by Tilman R Rohrer in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
good safety profile ( 6 , 7 ). Norditropin® (Novo Nordisk A/S) is currently the only GH replacement therapy approved internationally for the treatment of short stature in children with NS (in the United States, Canada, European Union, UK, Japan, Israel
Search for other papers by Régis Coutant in
Google Scholar
PubMed
Pediatric team of the Clinical Investigation Center 9302/INSERM, Hospital of Children, Toulouse, France
Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France
Search for other papers by Maithé Tauber in
Google Scholar
PubMed
Search for other papers by Béatrice Demaret in
Google Scholar
PubMed
Search for other papers by Robin Henocque in
Google Scholar
PubMed
Search for other papers by Yves Brault in
Google Scholar
PubMed
Search for other papers by François Montestruc in
Google Scholar
PubMed
Patient-Reported Outcomes Unit (PROQOL), UMR 1123, University Paris Cité, INSERM, Paris, France
Search for other papers by Olivier Chassany in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
Search for other papers by the QOLITHOR Study Group in
Google Scholar
PubMed
(%) Norditropin FlexPro® 32 (44.4%) 41 (36.6%) 26 (28.6%) 99 (36.0%) 20 (45.5%) 26 (37.7%) 19 (35.8%) 65 (39.2%) Saizen® 22 (30.6%) 19 (17.0%) 20 (22.0%) 61 (22.2%) 14 (31.8%) 15 (21.7%) 11 (20.8%) 40 (24.1%) Omnitrope
Medical Research Laboratories, Department of Endocrinology and Diabetes, Department of Pediatrics, Department of Endocrinology and Diabetes, Institute of Clinical Medicine, Aarhus University, Norrebrogade 44, DK-8000 Aarhus C, Denmark
Medical Research Laboratories, Department of Endocrinology and Diabetes, Department of Pediatrics, Department of Endocrinology and Diabetes, Institute of Clinical Medicine, Aarhus University, Norrebrogade 44, DK-8000 Aarhus C, Denmark
Search for other papers by Esben Thyssen Vestergaard in
Google Scholar
PubMed
Search for other papers by Morten B Krag in
Google Scholar
PubMed
Search for other papers by Morten M Poulsen in
Google Scholar
PubMed
Search for other papers by Steen B Pedersen in
Google Scholar
PubMed
Medical Research Laboratories, Department of Endocrinology and Diabetes, Department of Pediatrics, Department of Endocrinology and Diabetes, Institute of Clinical Medicine, Aarhus University, Norrebrogade 44, DK-8000 Aarhus C, Denmark
Search for other papers by Niels Moller in
Google Scholar
PubMed
Medical Research Laboratories, Department of Endocrinology and Diabetes, Department of Pediatrics, Department of Endocrinology and Diabetes, Institute of Clinical Medicine, Aarhus University, Norrebrogade 44, DK-8000 Aarhus C, Denmark
Search for other papers by Jens Otto Lunde Jorgensen in
Google Scholar
PubMed
Medical Research Laboratories, Department of Endocrinology and Diabetes, Department of Pediatrics, Department of Endocrinology and Diabetes, Institute of Clinical Medicine, Aarhus University, Norrebrogade 44, DK-8000 Aarhus C, Denmark
Search for other papers by Niels Jessen in
Google Scholar
PubMed
immediately before and immediately after an 8-day treatment period with either GH (Norditropin SimplexX; Novo Nordisk; 2 mg s.c. at 1000 h, last injection on day 7) or placebo (saline) injections in a randomized, double-blind, crossover manner. The study
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Nathalie Ly in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Sophie Dubreuil in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Sorbonne University, Paris, France
Search for other papers by Philippe Touraine in
Google Scholar
PubMed
Höybye C Carroll P Gordon MB Birkegård AC Kelepouris N Nedjatian N Weber MM . Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin
Search for other papers by Kennett Sprogøe in
Google Scholar
PubMed
Search for other papers by Eva Mortensen in
Google Scholar
PubMed
Search for other papers by David B Karpf in
Google Scholar
PubMed
Search for other papers by Jonathan A Leff in
Google Scholar
PubMed
-0526 ) 10.1210/jc.2007-0526 6 Pawlikowska-Haddal A . Growth hormone therapy with norditropin (somatropin) in growth hormone deficiency. Expert Opinion on Biological Therapy 2013 13 927 – 932 . ( doi:10.1517/14712598.2013.795941 ) 10
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Search for other papers by Bhuvanesh Mahendran in
Google Scholar
PubMed
Search for other papers by K Shrinivas Reddy in
Google Scholar
PubMed
Search for other papers by Jasmina Ahluwalia in
Google Scholar
PubMed
Search for other papers by Kim Vaiphei in
Google Scholar
PubMed
Search for other papers by Rakesh K Kochhar in
Google Scholar
PubMed
Search for other papers by Prakamya Gupta in
Google Scholar
PubMed
Search for other papers by Anand Srinivasan in
Google Scholar
PubMed
Search for other papers by Mahesh Prakash in
Google Scholar
PubMed
Search for other papers by Kanchan Kumar Mukherjee in
Google Scholar
PubMed
Search for other papers by Viral N Shah in
Google Scholar
PubMed
Search for other papers by Girish Parthan in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
. Acknowledgements The authors are thankful to Dr R J Dash Ex-Prof & Head, Department of Endocrinology, PGIMER, Chandigarh, India for manuscript editing and valuable suggestions. We also thank Novo Nordisk India Ltd for the generous gift of Norditropin Simplex
Search for other papers by Alessandro Ciresi in
Google Scholar
PubMed
Search for other papers by Stefano Radellini in
Google Scholar
PubMed
Search for other papers by Valentina Guarnotta in
Google Scholar
PubMed
Search for other papers by Maria Grazia Mineo in
Google Scholar
PubMed
Search for other papers by Carla Giordano in
Google Scholar
PubMed
.1210/jc.2005-0981 ) 10.1210/jc.2005-0981 30 Cohen P Bright GM Rogol AD Kappelgaard AM Rosenfeld RG & American Norditropin Clinical Trials Group . Effects of dose and gender on the growth and growth factor response to GH in GH